ThermoGenesis trims losses, inks Chinese distribution deal
ThermoGenesis Corp. (NSDQ:KOOL) recorded a loss of approximately $68,000, equal to about 0 cents per diluted share, on revenue of $7.0 million during the three months ended Sept. 30. That compares with a loss of $2.2 million, or 16 cents per diluted share, on revenue of $5.2 million during the same period last year. The Rancho Cordova, Calif.-based company also signed a distribution agreement covering China and Hong Kong for its products used to prepare cell concentrates, including stem cells, from bone marrow, at the point-of-care and in the laboratory.
Read more

DJO sales slide, but company trims losses
DJO Inc. subsidiary DJO Finance LLC reported a loss of $7.5 million on revenue of $233.6 million during the three months ended Oct. 2. That compares with profits of $11.3 million on revenue of $236.2 million during the same period last year.
Read more

GenMark losses narrow as revenue bounds upward
GenMark Diagnostics Inc. (NSDQ:GNMK) posted a loss of $4.9 million or 42 cent per diluted share, on revenues of $667,410 during the three months ended Sept. 30. That compares with a net loss of $5.7 million, or $1.13 per diluted share, on revenues of $255,138 during the same period last year.
Read more

CryoLife sales rise slightly as earnings dive
CryoLife Inc. (NYSE:CRY) posted a loss of $3.0 million or 11 cents per diluted share, on revenues of $28.4 million during the three months ended Sept. 30. That compares with profits of $1.9 million, or $7 cents per diluted share, on revenues of $28.2 million during the same period last year.
Read more

RTI posts losses on acquisition charge
RTI Biologics Inc. (NSDQ:RTIX) recorded a loss of $133.1 million, or $2.43 per diluted share, on sales of $41.8 million during the three months ended Sept. 30 That compares with net income of $2.3 million or 4 cents per diluted share, on sales of $42.8 million during the same period last year.
Read more

DexCom sales jump, but losses stay about even
DexCom Inc. (NSDQ:DXCM) reported a loss of $13.4 million, or 23 cents per diluted share, on sales of $11.7 million during the three months ended Sept. 30. That compares with a loss of $13.5 million, or 29 cents per diluted share, on sales of $7.3 million during the same period last year.
Read more

Symmetry sales rise, but income drops
Symmetry Medical Inc. (NYSE:SMI) posted profits of $3.5 million, or 10 cents per diluted share, on revenue of $ 91.5 million during the three months ended Oct. 2. That compares with profits $5.4 million, or 15 cents per diluted share, on sales of $87.2 million during the same period last year.
Read more

Rochester Medical net income up 23 percent
Rochester Medical Corp. (NSDQ:ROCM) reported profits of $172,019, or 1 cent per diluted share, on sales of $11.1 million during the three months ended Sept. 30. That compares with a loss of $229,255, or 2 cents per diluted share, on sales of $9.0 million during the same period last year.
Read more

Merit Medical dips into red ink after acquisition charges
Merit Medical Systems Inc. (NSDQ:MMSI) recorded a loss of $2.0 million, or 7 cents per diluted share, on revenues of $73.2 million during the three months ended Sept. 30. That compares with profits of $6.1 million, or 21 cents per diluted share, on revenues of $66.8 million during the same period last year.
Read more

Luminex revenues edge up, but so do losses
Luminex Corp. (NSDQ:LMNX) recorded a loss of approximately $727,000, or 2 cents per diluted share, on sales of $33.9 million during the three months ended Sept. 30. That compares with a loss of approximately $609,000, or 1 cent per diluted share, on revenues of $29.1 million during the same period last year.
Read more

Iridix sales rise and profits get a bump
Iridix Corp. (NYSE:IRIX) reported profits of $910,000 or 9 cents per diluted share, on sales of $10.8 million during the three months ended Sept. 30. That compares with profits of $646,000, or 7 cents per diluted share, on sales of $10.4 million during the same period last year.
Read more

InSite sales rise, as losses shrink
InSite Vision Inc. (OTC:INSV) recorded a loss of $2.3 million, or 2 cents per diluted share, on sales of $3.2 million during the three months ended Sept. 30. That compares with a loss of $3.1 million, or 3 cents per diluted share, on revenues of $2.2 million during the same period last year.
Read more

Genoptix profts cut in half
Genoptix Inc. (NSDQ:GXDX) posted net income of $4.4 million, or 24 cents per diluted share, on sales of $49.5 million during the three months ended Sept. 30. That compares with income of $9.5 million, or 53 cents per diluted share, on revenues of $50.8 million during the same period last year.
Read more

eResearchTechnology doubles revenues, but EPS static
eResearchTechnology Inc. (NSDQ:ERES) posted net income of $3.2 million, or 6 cents per diluted share, on sales of $45.1 million during the three months ended Sept. 30. That compares with income of $2.8 million, or 6 cents per diluted share, on revenues of $22.7 million during the same period last year.
Read more

Response Genetics doubles sales and slashes losses
Response Genetics Inc. (NSDQ:RGDX) posted a net loss $1.1 million, or 6 cents per diluted share, on sales of $5.6 million during the three months ended Sept. 30. That compares with a loss of $2.0 million, or 14 cents per diluted share, on sales of $2.3 million during the same period last year.
Read more